Streetbeat News

Regulatory

CLRB

Cellectar Biosciences, Inc. (NASDAQ:CLRB) has received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for its lead small-molecule drug candidate, iopofosine I 131, for Waldenstrom's macroglobulinemia (WM) in patients who have received two or more prior treatment regimens. The company expects to release top-line data from the CLOVER-WaM pivotal trial in Q4 2023 and submit its NDA in March 2024. The U.S. FDA has also granted Fast Track Designation for the drug for WM patients, as well as for multiple myeloma and diffuse large B-cell lymphoma (DLBCL).

Portfolio Pulse from Benzinga Newsdesk

September 18, 2023 | 12:42 pm

MBRX

Moleculin Biotech, Inc. (NASDAQ:MBRX) announced that its drug Annamycin has shown no evidence of cardiotoxicity in a total of 62 subjects across three clinical trials. The drug, a next-generation anthracycline, has demonstrated safety and early activity across multiple clinical studies. The company believes Annamycin could be an effective treatment across multiple oncology indications.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2023 | 12:42 pm

BLTH

SGII

American Battery Materials, Inc. (OTC:BLTH) reaffirmed its commitment to the proposed $120M merger with Seaport Global Acquisition II Corp. (NASDAQ:SGII) despite Seaport Global receiving a delisting warning letter from NASDAQ. The merger is expected to result in ABM becoming a wholly owned subsidiary of SGII and the combined company will be renamed 'American Battery Materials Holdings'.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2023 | 12:36 pm

SPY

Treasury Secretary Janet Yellen is scheduled to appear live on CNBC at 10 a.m. ET today, according to Reuters. The SPY ETF may be discussed during the interview.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2023 | 12:28 pm

MEIP

MEI Pharma has received director nominations from Anson and Cable Car. The company's board will review these nominations in line with its corporate governance guidelines and fiduciary duties to all stockholders. No action is required from stockholders at this time.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2023 | 12:16 pm

TOI

The Oncology Institute (TOI) has regained compliance with Nasdaq's listing requirements, ensuring its continued listing on the exchange.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2023 | 12:06 pm

TCON

TRACON Pharmaceuticals announced that its ENVASARC Phase 2 pivotal trial has exceeded the futility threshold at the final interim analysis and will continue as planned.

Portfolio Pulse from Bill Haddad

September 18, 2023 | 12:04 pm

SHOT

Safety Shot is planning to develop a detox product for alcohol poisoning and intends to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA).

Portfolio Pulse from Bill Haddad

September 18, 2023 | 12:04 pm

OCX

Oncocyte has presented new clinical data at the European Society of Organ Transplant Conference, demonstrating that its Vitagraft Assay can detect antibody-mediated transplant rejection 10 months earlier than commonly used monitoring protocols.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2023 | 12:03 pm

CME

CME Group, a leading derivatives marketplace, announced the launch of Cobalt Hydroxide futures on October 23, pending regulatory reviews. This is the fourth battery metals futures contract by CME Group, aimed at addressing the evolving hedging needs in the growing electric vehicle sector. The futures will be financially-settled based on Fastmarkets' cobalt hydroxide price assessment. The new contract will be listed by COMEX under the product name Cobalt Hydroxide CIF China (Fastmarkets) futures.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2023 | 12:01 pm